Effects of mexiletine, propafenone and flecainide on signal-averaged electrocardiogram.
The effects of mexiletine, propafenone and flecainide on the parameters of signal-averaged electrocardiogram in 40 subjects with symptomatic and repetitive ventricular arrhythmias were studied. Mexiletine (n = 16) suppressed ventricular arrhythmias in 10 patients and did not produce any significant changes in filtered QRS duration (fQRS), root mean square voltage of the final 40 ms of filtered QRS (RMS40) or low amplitude terminal component duration (LAS40). Acute (n = 8, 450 mg) and chronic (n = 16, 600-1200 mg.day-1) administration of propafenone determined a significant increase in fQRS (from 123 +/- 2.2 to 139 +/- 3 ms) and a reduction in RMS40 (from 54 +/- 8.8 to 34 +/- 6.7 microV); as a consequence the incidence of ventricular late potentials rose from 43 to 62%. The observed effects were independent of anti-arrhythmic efficacy, which was 86% for this drug. Acute (n = 8, 200 mg) and chronic (n = 13, 200-300 mg.day-1) administration of flecainide was associated with a marked prolongation in fQRS (from 123 +/- 2.8 to 138 +/- 4.1 ms) and a reduction in RMS40 (from 69 +/- 11.5 to 47 +/- 11 microV); thus determining an increase in the incidence of ventricular late potentials from 29 to 48%. Changes in signal-averaged electrocardiogram were not related to drug efficacy, which was 81%. These data indicate that 1c anti-arrhythmic drugs consistently modified the parameters of signal-averaged electrocardiogram; the observed changes might reflect an inhomogeneous slowing of intramyocardial impulse propagation.
Lombardi
F
F
Istituto Ricerche Cardiovascolari, Cardiologia Ospedale, L. Sacco, Centro Fidia, Università Milano, Italy.
Finocchiaro
M L
ML
Dalla Vecchia
L
L
Rech
R
R
Castelli
A
A
Pastine
J
J
Cappiello
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015716:Electrocardiography, Ambulatory / Q000187:drug effects* / Q000295:instrumentation; D005260:Female; D005424:Flecainide / Q000008:administration & dosage* / Q000009:adverse effects; D006331:Heart Diseases / Q000150:complications / Q000188:drug therapy; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011405:Propafenone / Q000008:administration & dosage* / Q000009:adverse effects; D012815:Signal Processing, Computer-Assisted / Q000295:instrumentation*; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology
D008801:Mexiletine; D011405:Propafenone; D005424:Flecainide